Related Experiment Videos
Single isomer technetium-99m tamoxifen conjugates.
1Department of Chemistry, University of Western Ontario, London, Ontario, Canada N6A 5B7. dhunter@julian.uwo.ca
Bioconjugate Chemistry
|March 22, 2000
Summary
Researchers developed technetium-99m-labeled agents targeting estrogen receptors for breast cancer imaging. However, biological evaluations showed limited estrogen receptor binding for these tamoxifen chelates.
Area of Science:
- Radiochemistry
- Oncology
- Pharmacology
Background:
- Developing targeted radiopharmaceuticals is crucial for sensitive breast cancer detection.
- Estrogen receptors are key targets for breast cancer therapies and imaging.
Purpose of the Study:
- To synthesize and characterize technetium-99m-labeled tamoxifen conjugates as potential breast cancer imaging agents.
- To evaluate the estrogen receptor binding affinity of the developed agents.
Main Methods:
- Conjugation of an N(2)S(2) bifunctional chelator to Z- and E-aminotamoxifens.
- Chelation of bioconjugates with technetium-99m and rhenium.
- Characterization of isomers and radiochemical purity using chromatography.
- In vitro and in vivo biological evaluation for estrogen receptor binding.
Main Results:
- Successful synthesis of technetium-99m-labeled tamoxifen conjugates with >80% radiochemical yield and >99% purity.
- Characterization of anti and syn isomers for rhenium complexes and identification of the anti isomer for technetium-99m complexes.
- Demonstrated very limited estrogen receptor binding in both in vitro and in vivo studies.
Conclusions:
- Technetium-99m-labeled tamoxifen conjugates were synthesized with high purity and yield.
- The developed agents exhibited poor estrogen receptor binding, limiting their potential as imaging agents for estrogen receptor-positive breast cancer.